Work

Long-term Results of Ponatinib in CP-CML: 4-Year Minimum Follow-up of a Phase 1 Trial

Year: 2015

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2015.07.072

Authors: Hagop M. Kantarjian, Moshe Talpaz, Jorge E. Cortes, Neil P. Shah, Dale L. Bixby, Ian W. Flinn, Thomas J. O’Hare, Simin Hu, Victor M. Rivera, Tim Clackson, Maureen G. Conlan, Frank G. Haluska, Brian J. Druker, Michael W. Deininger, Michael J. Mauro

Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, U-M Rogel Cancer Center, University of California, San Francisco, Sarah Cannon, Huntsman Cancer Institute, ARIAD Pharmaceuticals (United States), OHSU Knight Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2213995114

FWCI:

Cites:

Cited by:

Related to: 10